HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time
31 Outubro 2023 - 9:31AM
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac
technology company that has developed the first and only credit
card-size 3D-vector electrocardiogram (VECG) platform for patient
use at home, allowing for the creation of rich data for AI, will
hold a conference call on Tuesday November 14, 2023 at 4:30 p.m.
Eastern time to discuss its results for the third quarter ended
September 30, 2023, and will be reviewing recent announcements,
ongoing initiatives, and anticipated 2024 milestones. A press
release detailing these results will be issued prior to the
call.
HeartBeam CEO and Founder Branislav Vajdic, PhD, President
Robert Eno and CFO Richard Brounstein will host the conference
call, followed by a question-and-answer period. The conference call
will be accompanied by a presentation, which can be viewed during
the webcast or accessed via the investor relations section of the
Company’s website here.
To access the call, please use the following information:
Date:
Tuesday November 14, 2023
Time:
4:30 p.m. Eastern time (1:30 p.m.
Pacific time)
Dial-in:
1-877-704-4453
International Dial-in:
1-201-389-0920
Conference Code:
13741784
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1637601&tp_key=06cb7fdae7
A telephone replay will be available approximately three hours
after the call and will run through February 14, 2024, by dialing
1-844-512-2921 from the U.S., or 1-412-317-6671 from international
locations, and entering replay pin number: 13741784. The replay can
also be viewed through the webcast link above and the presentation
utilized during the call will be available in the company’s
investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform
intended for patient use at home. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to assess their cardiac symptoms quickly and easily, so
care can be expedited, if required. HeartBeam AIMIGo™ is the first
and only credit card-sized 12-lead output ECG device coupled with a
smart phone app and cloud-based diagnostic software system to
facilitate remote evaluation of cardiac symptoms. By collecting 3D
signals of the heart’s electrical activity, HeartBeam AIMIGo has
the potential to provide unparalleled data for the development of
AI algorithms. HeartBeam AIMIGo has not yet been cleared by the US
Food and Drug Administration (FDA) for marketing in the USA or
other geographies. For more information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our Forms 10-K, 10-Q and other reports filed with the SEC and
available at www.sec.gov. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031406279/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us Media Contact: media@heartbeam.com
HeartBeam (NASDAQ:BEAT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
HeartBeam (NASDAQ:BEAT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024